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SAFE HANDLING OF HAZARDOUS DRUGS
DIRECTIONS IN HEALTH-SYSTEM PHARMACY™
SEPTEMBER  202128
T HE DRUG QUALITY and Security Act was signed into law on November 27, 2013, and included the Title 2 Drug 
Supply Chain and Security Act (DSCSA).1 
This legislation was introduced to enact 
a federal prescription drug safety standard 
to decrease contamination, counterfeiting, 
diversion, and otherwise harmful illicit 
activities. It also improves the detection 
and elimination of potentially unsafe 
drugs from the drug supply chain to 
protect US consumers. 
DSCSA required that several key initia-
tives be implemented and maintained to 
ensure supply chain safety. These have 
included building an interoperable system 
for the handling of suspected counterfeit 
products and product serialization, tracing, 
and verification. Components of this 
regulation have been phased in over time, 
and manufacturers and suppliers have spent 
unspecified funds relabeling, retooling, 
and working on the supply chain with the 
ultimate goal of unit-level traceability by 
November 27, 2023.2-4 
DSCSA was broad in scope, encompassing 
prescription drugs in finished form for admin-
istration (capsules, tablets, and lyophilized 
powder for reconstitution). It does not cover, 
or exempts, several items that are difficult to 
monitor, including blood or blood compo-
nents for transfusion; compounded, homeo-
pathic, and imaging drugs; intravenous and 
OTC products; medical gases; and radioactive 
biologics and drugs.
Critical components of DSCSA that 
pharmacists need to know and continuously 
monitor include the following:
•  Product tracing. Supply chain 
participants have been required to 
electronically share product transaction 
history with the next member of the 
chain (interoperable data) until the 
member is providing the medication 
to the final user.2 This part often has 
included significant documentation 
if the pharmacies are transferring 
medication between 2 locations. This 
can now be done electronically. Also, 
DSCSA required that the transaction, 
history, information, and statement be 
provided upon a change of ownership 
between trading partners.1 Therefore, 
if pharmacies loan products between 
pharmacies under different ownership, 
they would be accountable to provide 
the statements to the entity  
where the product is loaned and main-
tain records for 6 years. Exceptions 
include distribution among hospitals 
under common control, intracompany 
distributions, and public health emer-
gencies dispensed under a prescription.1
•  Serialization. For serialization, a 
unique serial number is added to each 
saleable unit of each prescription 
product, which has been linked to the 
information about the product’s batch 
number, expiration date, and origin. 
This process allows end-to-end tracing 
and gives businesses the ability to 
manage and track many transactions 
and large data sets between trading 
partners. The key for pharmacies is that 
these systems are interoperable.4
•  Suspect product. This is a product 
for which there is reason to think that 
it appears unfit for distribution because 
it could result in serious adverse health 
consequences or death or it is poten-
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tially counterfeit, diverted, stolen, or 
the subject of a fraudulent transaction. 
In case of any of these events, the phar-
macy will need policies and procedures 
in place and a segregated area to store 
the product until a resolution is found.4
•  Transaction history. This is a state-
ment in electronic or paper form, 
including the information for each 
prior transaction going back to the 
product manufacturer.
•  Transaction information. This 
includes the names and addresses of the 
businesses from which and to which 
ownership was transferred, dosage 
form, established or proprietary name of 
a product, lot size, National Drug Code 
container size, number of containers, 
product strength, and shipment and 
transaction dates.
•  Transaction statement. This is a 
document or electronic statement 
showing that the entity transferring 
ownership in a transaction did not  
deliberately provide false transaction 
information, knowingly alter the 
transaction history, or intentionally 
ship an illegitimate or suspect product; 
had processes and systems in place to 
comply with verification requirements 
under the law; received the product 
from an individual authorized as 
required under DSCSA; and received 
transaction information and a statement 
from the prior owner of the product, as 
mandatory under the law.
•  Verification. In the event of a 
suspect product inquiry, supply chain 
companies must be able to produce 
relevant transaction documentation 
within 24 hours (dispensers have 48 
hours). Businesses need a storage and 
retrieval system that quickly supports 
these queries. The verification process 
requires a system be put into place to 
allow for the quarantine and investiga-
tion of suspect products and a mech-
anism to notify the FDA and trading 
partners if an illegitimate product  
is found.5
Conclusion
DSCSA was enacted and phased in over the 
past several years with the intent to help 
secure the pharmaceutical supply chain. 
Pharmacy health-system managers should 
continue to work with FDA-approved 
partners to analyze their data require-
ments, operations, and technology and to 
understand their responsibilities around 
tracking and tracing. ■
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